Document is current
Any future updates will be listed below
-
Authors
Medeiros, Gustavo C. https://orcid.org/0000-0002-0091-1192
Demo, Isabella
Goes, Fernando S. https://orcid.org/0000-0001-6262-8264
Zarate, Carlos A. Jr
Gould, Todd D.
- License Information
-
More Information
Article History
Received: 27 November 2023
Revised: 1 November 2024
Accepted: 6 November 2024
First Online: 29 November 2024
Competing interests
: GCM, ID, FSG, CAZ, and TDG have no consulting or grant funding to disclose in the prior 3 years. TDG was supported by NIH/NIMH R01MH107615 and U.S. Department of Veterans Affairs Merit Awards 1I01BX004062 and 1I01BX006018. Funding for this work was provided in part by the Intramural Research Program at the National Institute of Mental Health, National Institutes of Health (IRP-NIMH-NIH; ZIAMH002857). The contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs, the National Institutes of Health, the Department of Health and Human Services, or the United States Government. TDG is listed as an inventor in patents and patent applications related to the pharmacology and use of a ketamine metabolites, including (2 <i>R</i>,6 <i>R</i>)-hydroxynorketamine, in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. TDG has assigned his patent rights to the University of Maryland, Baltimore, but will share a percentage of any royalties that may be received by the University of Maryland, Baltimore. CAZ is listed as a co-inventor on a patent for the use of ketamine in major depression and suicidal ideation; as a co-inventor on a patent for the use of (2 <i>R</i>,6 <i>R</i>)-hydroxynorketamine, (<i>S</i>)-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of (<i>R,S</i>)-ketamine metabolites in the treatment of depression and neuropathic pain; and as a co-inventor on a patent application for the use of (2 <i>R</i>,6 <i>R</i>)-hydroxynorketamine and (2<i>S</i>,6<i>S</i>)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post-traumatic stress disorders. He has assigned his patent rights to the U.S. government but will share a percentage of any royalties that may be received by the government.
